Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ReNeuron poised for stroke treatment trials

Mon, 11th Jan 2010 08:44

Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year.ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is reached, the trial will get underway in the UK soon. ReNeuron said it also is now proceeding with late pre-clinical testing of the ReN009 therapy for peripheral arterial disease and will continue to liase with the regulatory authorities both in the UK and in other territories, including the US, ahead of the commencement of initial clinical trials next year.
More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.